Company intelligence / Profile preview
Plethora Solutions
Chalgrove, United Kingdomplethorasolutions.co.uk ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
PSD502/Fortacin™, a topical treatment for premature ejaculation developed by Plethora Solutions with partner Sciele Pharma/Shionogi, met all primary and secondary endpoints in European Phase III pivotal trials demonstrating significant patient satisfaction and tolerability without systemic side effects. This product obtained European marketing authorization.
- Therapeutic areas
- Women's HealthMen's HealthUrologyNephrology
- Modalities
- Small molecule drugs primarily
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Sciele Pharma/Shionogi partnership notably for PE drug development/commercialization
Beyond the preview
Go deeper on Plethora Solutions.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Plethora Solutions.